Aurinia Pharm Ord (AUPH)

Feb 27, 2025, 2:11 PM EST - 4 weeks ago

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Feb 27, 2025, 10:32 AM EST - 4 weeks ago

Aurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 6:00 AM EST - 4 weeks ago

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Feb 21, 2025, 4:09 PM EST - 5 weeks ago

Aurinia Pharmaceuticals: There's Still Time For Sales Growth

Feb 20, 2025, 4:05 PM EST - 5 weeks ago

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Jan 22, 2025, 12:29 PM EST - 2 months ago

3 Biotech Stocks With Notable Insider Buying

AZN COGT JAZZ ONC XBI ZYME

Nov 18, 2024, 5:53 PM EST - 4 months ago

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Nov 15, 2024, 6:00 AM EST - 4 months ago

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Nov 14, 2024, 6:00 AM EST - 4 months ago

Aurinia to Participate in Jefferies London Healthcare Conference

Nov 8, 2024, 12:15 PM EST - 5 months ago

Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon

Nov 7, 2024, 11:44 AM EST - 5 months ago

Aurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:10 AM EST - 5 months ago

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Nov 7, 2024, 6:00 AM EST - 5 months ago

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Oct 30, 2024, 4:05 PM EDT - 5 months ago

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Oct 11, 2024, 6:00 AM EDT - 6 months ago

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Sep 24, 2024, 8:10 AM EDT - 6 months ago

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Sep 19, 2024, 12:54 PM EDT - 6 months ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

CORT VRDN

Sep 19, 2024, 7:55 AM EDT - 6 months ago

Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment

Sep 18, 2024, 4:41 AM EDT - 7 months ago

Aurinia Pharmaceuticals: This Recovery Can Continue

Sep 13, 2024, 6:00 AM EDT - 7 months ago

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2024, 4:05 PM EDT - 7 months ago

Aurinia Announces Board Restructuring

Sep 5, 2024, 6:00 AM EDT - 7 months ago

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aug 28, 2024, 6:00 AM EDT - 7 months ago

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 8 months ago

Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board

Aug 1, 2024, 1:52 PM EDT - 8 months ago

Aurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 6:00 AM EDT - 8 months ago

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Jul 19, 2024, 6:00 AM EDT - 9 months ago

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Jul 11, 2024, 3:27 PM EDT - 9 months ago

ILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGM

Jul 5, 2024, 2:10 PM EDT - 9 months ago

Aurinia Pharmaceuticals Appears Undervalued

Jul 2, 2024, 6:00 AM EDT - 9 months ago

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Jun 14, 2024, 12:16 PM EDT - 10 months ago

Aurinia Announces 2024 Annual General Meeting Results

Jun 5, 2024, 6:00 AM EDT - 10 months ago

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Jun 4, 2024, 5:30 PM EDT - 10 months ago

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Jun 3, 2024, 6:30 PM EDT - 10 months ago

Aurinia Provides Update on Proxy Statement

Jun 3, 2024, 8:00 AM EDT - 10 months ago

Aurinia Pharmaceuticals Shareholder Urges Fellow Shareholders to Withhold Support for CEO Peter Greenleaf

Jun 2, 2024, 10:18 AM EDT - 10 months ago

3 Biotech Names Under $10 I Own

FOLD VYGR

May 30, 2024, 6:00 AM EDT - 10 months ago

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

May 14, 2024, 6:00 AM EDT - 11 months ago

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024

May 9, 2024, 6:00 AM EDT - 11 months ago

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

May 7, 2024, 9:00 AM EDT - 11 months ago

Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value

May 7, 2024, 6:00 AM EDT - 11 months ago

Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference

May 2, 2024, 4:49 PM EDT - 11 months ago

Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)

May 2, 2024, 12:03 PM EDT - 11 months ago

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript

May 2, 2024, 6:00 AM EDT - 11 months ago

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

May 1, 2024, 6:00 AM EDT - 1 year ago

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month

Apr 30, 2024, 1:00 PM EDT - 1 year ago

Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going

Apr 30, 2024, 6:00 AM EDT - 1 year ago

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program

Apr 18, 2024, 11:26 AM EDT - 1 year ago

Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024

Apr 16, 2024, 10:48 AM EDT - 1 year ago

UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Apr 15, 2024, 6:00 AM EDT - 1 year ago

Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024